关注交联技术的发展及巩膜交联技术在控制近视发展中的潜在应用价值  

Pay attention to the development of cross-linking technology and the potential application value of scleral cross-linking technology in controlling myopia development

作　　者：曹宇 苗泽群 王凯[2] 王乐今[2] Cao Yu;Miao Zequn;Wang Kai;Wang Lejin(Peking University People′s Hospital,Beijing 100044,China;Department of Ophthalmology,Peking University People′s Hospital,Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases,Beijing 100044,China)

机构地区：[1]北京大学人民医院眼科,100044 [2]北京大学人民医院眼视光中心、视网膜脉络膜疾病诊治研究北京市重点实验室,100044

出　　处：《中华眼科医学杂志（电子版）》2023年第2期65-69,共5页Chinese Journal of Ophthalmologic Medicine(Electronic Edition)

基　　金：国家自然科学基金项目(31427801);首都卫生发展科研专项基金项目(2022-1G-4083)。

摘　　要：近视是视力损伤的常见原因之一,而病理性近视由于存在巩膜结构的重塑,在屈光状态异常之外还存在眼部结构的改变。近年来,许多学者对控制近视发展的方法进行了探索,而通过交联技术增强巩膜强度的方法备受关注。交联技术包括物理方法和化学方法,目前最常用的是紫外线-核黄素交联法。作为一种既往成熟应用于各种角膜疾病治疗的手段,巩膜交联技术用以增强巩膜强度的研究为近视发展的控制提供了重要思路。本文中笔者对近年来交联技术的发展和巩膜交联技术用于控制近视发展的研究与应用进行评述。Myopia is one of the common causes of visual impairment,and pathological myopia,due to the reshaping of the sclera structure,also involves changes in the eye structure in addition to abnormal refractive status.In recent years,methods to control the development of myopia have been explored,and the method of enhancing scleral strength through cross-linking technology has been paid more attention.Crosslinking technology includes physical methods and chemical methods.At present,the most commonly used method is ultraviolet Riboflavin crosslinking.As a previously mature method for the treatment of various corneal diseases,understanding scleral cross-linking technology using enhancing scleral strength provides important ideas for the control of myopia development.In this paper,the research and application of scleral cross-linking technology in controlling the development of myopia were reviewed in recent years.

关 键 词：近视 交联 巩膜 角膜 

分 类 号：R778.11[医药卫生—眼科]